Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 6NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Liver Neoplasms 3Carcinoma, Hepatocellular 3Colorectal Neoplasms 2Biliary Tract Neoplasms 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1

Interventions

tremelimumab 2pembrolizumab 2Radiofrequency Ablation 2Oxaliplatin 2Cryosurgery 2Capecitabine 2trametinib 1durvalumab 1Tomography, X-Ray Computed 1Radiation 1Positron-Emission Tomography 1Magnetic Resonance Imaging 1Hydroxychloroquine 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Biliary Tract Neoplasms × tremelimumab × Clear all
NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
54 enrolled 14 charts
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT01853618 2019-12-10

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
61 enrolled 18 charts
Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡